Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
The impact of glucocorticoid therapy on immune responses to COVID-19 vaccination or infection in rituximab-treated patients with autoimmune disorders

The impact of glucocorticoid therapy on immune responses to COVID-19 vaccination or infection in rituximab-treated patients with autoimmune disorders

Remdesivir resistance in renal transplant patients with long COVID-19

Remdesivir resistance in renal transplant patients with long COVID-19

Analysis finds variation in the management of mantle cell lymphoma across clinical settings

Analysis finds variation in the management of mantle cell lymphoma across clinical settings

A cancer patient who had SARS-CoV-2 for over eight months

A cancer patient who had SARS-CoV-2 for over eight months

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Molecular profiling of diseased joints could transform treatment for rheumatoid arthritis patients

Molecular profiling of diseased joints could transform treatment for rheumatoid arthritis patients

Study shows how MS patients treated with Rituximab react to COVID-19 vaccination

Study shows how MS patients treated with Rituximab react to COVID-19 vaccination

Antibody-based treatment, endogenous immune responses, and within-host SARS-CoV-2 evolution in immunocompromised patients

Antibody-based treatment, endogenous immune responses, and within-host SARS-CoV-2 evolution in immunocompromised patients

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

Impact of B-cell depletion therapy on hospitalized COVID-19 patients

Impact of B-cell depletion therapy on hospitalized COVID-19 patients

Study explores immune escape mutations caused by prolonged viral shedding in immunocompromised COVID-19 patient

Study explores immune escape mutations caused by prolonged viral shedding in immunocompromised COVID-19 patient

Severe COVID-19 outcomes in breakthrough infections in patients being treated with B cell depleting therapy

Severe COVID-19 outcomes in breakthrough infections in patients being treated with B cell depleting therapy

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

Immunosuppressed patients can benefit from COVID-19 booster vaccination, study shows

Immunosuppressed patients can benefit from COVID-19 booster vaccination, study shows

Combination treatment can provide long remissions for young patients with chronic lymphocytic leukemia

Combination treatment can provide long remissions for young patients with chronic lymphocytic leukemia

NEI researchers identify unique population of B cells that tamps down the immune system

NEI researchers identify unique population of B cells that tamps down the immune system

Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies

Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies

Results of high-impact clinical trials could affect kidney-related medical care

Results of high-impact clinical trials could affect kidney-related medical care